Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer now identifies the site revision as v3.8.0 instead of v3.7.2. The study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T19:06:44.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH transition in terminology, saying agencies are using “Super Intelligence” in place of “Artificial Intelligence” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T22:22:55.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision number changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T22:28:32.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1, while the study record continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:16:21.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The study page now presents an access-denied error (403), replacing the prior study content with a standard 403 page and site footer.
    Difference
    20%
    Check dated 2026-09-19T20:32:58.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The page shows a new revision tag, updating the version from v3.6.5 to v3.6.6, which signals a minor update to the record. No study details or user-facing information appear to be affected.
    Difference
    0.1%
    Check dated 2026-08-29T19:03:01.000Z thumbnail image

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.